

does not contain tyrosines or tryptophans that can add to the fluorescence and complicate the analyses. This phage was generated before we understood the importance of iron for  $\alpha$ -synuclein biochemistry (hence; the binding site was not specifically targeted against iron binding). Even so, incubating a 10- fold excess of peptide with  $\alpha$ -synuclein reduces iron-induced  $\alpha$ -synuclein aggregation by 38%.

*A4*  
*CONC.*

---

**In the Claims:**

*A5*

21. (Amended) The method of claim 20, wherein the peptide is selected from the group consisting of: WRQTRKD (SEQ ID NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3); RRRGMAI (SEQ ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO: 6); SLKRLPK (SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID NO: 9); HLYHHKT (SEQ ID NO: 10); THIHHPS (SEQ ID NO: 11); and MMMMMRL (SEQ ID NO: 12).

22. (Amended) The method of claim 21, wherein the peptide is selected from the group consisting of: THRLPSR (SEQ ID NO: 5); SLKRLPK (SEQ ID NO: 7); THIHHPS (SEQ ID NO: 11); and MMMMMRL (SEQ ID NO: 12).

23. (Amended) The method of claim 22, wherein the peptide is SLKRLPK (SEQ ID NO: 7).

*A6*

25. (Amended) The method of claim 24, whererin the agent is selected from the group consisting of: WRQTRKD (SEQ ID NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3); RRRGMAI (SEQ ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO: 6); SLKRLPK (SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID NO: 9); HLYHHKT (SEQ ID NO: 10); THIHHPS (SEQ ID NO: 11); and MMMMMRL (SEQ ID NO: 12).

26. (Amended) The method of claim 25, wherein the agent is selected from the group consisting of: THRLPSR (SEQ ID NO: 5); SLKRLPK (SEQ ID NO: 7); THIHHPS (SEQ ID NO: 11); and MMMMMRL (SEQ ID NO: 12).

WOLOZIN, Benjamin *et al.*

Serial No.: 09/901,187

Page 5

A6  
CONT.  
27. (Amended) The method of claim 26, wherein the peptide is SLKRLPK (SEQ ID NO: 7).

A7  
35. (Amended) The composition of claim 34, wherein the peptide is selected from the group consisting of: WRQTRKD (SEQ ID NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3); RRRGMAI (SEQ ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO: 6); SLKRLPK (SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID NO: 9); HLYHHKT (SEQ ID NO: 10); THIHHPS (SEQ ID NO: 11); and MMMMMRRL (SEQ ID NO: 12).

36. (Amended) The composition of claim 35, wherein the peptide is selected from the group consisting of: THRLPSR (SEQ ID NO: 5); SLKRLPK (SEQ ID NO: 7); THIHHPS (SEQ ID NO: 11); and MMMMMRRL (SEQ ID NO: 12).

37. (Amended) The composition of claim 36, wherein the peptide is SLKRLPK (SEQ ID NO: 7).

A8  
40. (Amended) The peptide of claim 39, wherein the peptide comprises a sequence selected from the group consisting of: WRQTRKD (SEQ ID NO: 1); HYAKNPI (SEQ ID NO: 2); ATINKSL (SEQ ID NO: 3); RRRGMAI (SEQ ID NO: 4); THRLPSR (SEQ ID NO: 5); TKHGPRK (SEQ ID NO: 6); SLKRLPK (SEQ ID NO: 7); RLRGRNQ (SEQ ID NO: 8); WPFHHHR (SEQ ID NO: 9); HLYHHKT (SEQ ID NO: 10); THIHHPS (SEQ ID NO: 11); and MMMMMRRL (SEQ ID NO: 12).

41. (Amended) The peptide of claim 40, wherein the peptide comprises a sequence selected from the group consisting of: THRLPSR (SEQ ID NO: 5); SLKRLPK (SEQ ID NO: 7); THIHHPS (SEQ ID NO: 11); and MMMMMRRL (SEQ ID NO: 12).

42. (Amended) The peptide of claim 41, which comprises the sequence SLKRLPK (SEQ ID NO: 7).